These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19104507)

  • 1. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer.
    Tabata K; Watanabe M; Naruishi K; Edamura K; Satoh T; Yang G; Abdel Fattah E; Wang J; Goltsov A; Floryk D; Soni SD; Kadmon D; Thompson TC
    Prostate Cancer Prostatic Dis; 2009; 12(3):301-9. PubMed ID: 19104507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model.
    Satoh T; Saika T; Ebara S; Kusaka N; Timme TL; Yang G; Wang J; Mouraviev V; Cao G; Fattah el MA; Thompson TC
    Cancer Res; 2003 Nov; 63(22):7853-60. PubMed ID: 14633713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
    Fujita T; Timme TL; Tabata K; Naruishi K; Kusaka N; Watanabe M; Abdelfattah E; Zhu JX; Ren C; Ren C; Yang G; Goltsov A; Wang H; Vlachaki MT; Teh BS; Butler EB; Thompson TC
    Gene Ther; 2007 Feb; 14(3):227-36. PubMed ID: 17024109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model.
    Nasu Y; Bangma CH; Hull GW; Lee HM; Hu J; Wang J; McCurdy MA; Shimura S; Yang G; Timme TL; Thompson TC
    Gene Ther; 1999 Mar; 6(3):338-49. PubMed ID: 10435084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines.
    Hull GW; Mccurdy MA; Nasu Y; Bangma CH; Yang G; Shimura S; Lee HM; Wang J; Albani J; Ebara S; Sato T; Timme TL; Thompson TC
    Clin Cancer Res; 2000 Oct; 6(10):4101-9. PubMed ID: 11051263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer.
    Nasu Y; Bangma CH; Hull GW; Yang G; Wang J; Shimura S; McCurdy MA; Ebara S; Lee HM; Timme TL; Thompson TC
    Prostate Cancer Prostatic Dis; 2001; 4(1):44-55. PubMed ID: 12497062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model.
    Saika T; Kusaka N; Mouraviev V; Satoh T; Kumon H; Timme TL; Thompson TC
    Cancer Gene Ther; 2006 Jan; 13(1):91-8. PubMed ID: 16052232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer.
    Wang H; Yang G; Timme TL; Fujita T; Naruishi K; Frolov A; Brenner MK; Kadmon D; Thompson TC
    Cancer Gene Ther; 2007 Oct; 14(10):819-27. PubMed ID: 17627292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines.
    Khatri A; Husaini Y; Ow K; Chapman J; Russell PJ
    Clin Cancer Res; 2009 Apr; 15(7):2323-34. PubMed ID: 19318483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetracycline-regulated intratumoral expression of interleukin-3 enhances the efficacy of radiation therapy for murine prostate cancer.
    Tsai CH; Hong JH; Hsieh KF; Hsiao HW; Chuang WL; Lee CC; McBride WH; Chiang CS
    Cancer Gene Ther; 2006 Dec; 13(12):1082-92. PubMed ID: 16841082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model.
    Tabata K; Kurosaka S; Watanabe M; Edamura K; Satoh T; Yang G; Abdelfattah E; Wang J; Goltsov A; Floryk D; Thompson TC
    Gene Ther; 2011 Oct; 18(10):969-78. PubMed ID: 21512508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adenovirus-mediated combined gene therapy of interleukin-18 and interleukin-12 for prostate cancer: an experimental study].
    Cheng B; Nong SJ; Zhang YP
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(20):1590-3. PubMed ID: 24028732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene-modified bone marrow cell therapy for prostate cancer.
    Wang H; Thompson TC
    Gene Ther; 2008 May; 15(10):787-96. PubMed ID: 18385769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Construction of a RU486 inducible recombinant adenoviral vector carrying murine interleukin-12 gene and experimental treatment of colonic carcinoma].
    Chen J; Liu XS; Wang F; Xue XC; Fang GE; Su CQ; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1372-6. PubMed ID: 19671324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model.
    Hong X; Miller C; Savant-Bhonsale S; Kalkanis SN
    Neurosurgery; 2009 Jun; 64(6):1139-46; discussion 1146-7. PubMed ID: 19487894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
    Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
    Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
    Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
    Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
    J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
    Darnel AD; Behmoaram E; Vollmer RT; Corcos J; Bijian K; Sircar K; Su J; Jiao J; Alaoui-Jamali MA; Bismar TA
    Clin Cancer Res; 2009 Feb; 15(4):1376-83. PubMed ID: 19228738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.